AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

- 1. (previously presented) A method of treating cancer by chemo-brachytherapy comprising administering to a subject by intra-tumoral administration a pharmaceutical composition comprising a cytotoxic drug and a porous silicon carrier material.
- 2. (currently amended) The method according to claim 1 wherein the porous silicon carrier material is doped or undoped silicon, germanium, silicon carbide or silicon nitride.
 - 3. (canceled).
- 4. (previously presented) The method according to claim 1 wherein the silicon is resorbable.
- 5. (previously presented) The method according to claim 4 where the resorbable silicon is mesoporous.
- 6. (previously presented) The method according to claim 1 wherein the cytotoxic drug is incorporated into the pores of the porous carrier material.
- 7. (previously presented) The method according to claim 1 wherein the cytotoxic drug is present in an amount of from 15% to 85% by weight, based on the weight of the composition.
- 8. (previously presented) The method according to claim 1 wherein the cytotoxic drug is selected from chlorambucil and paclitaxel.
- 9. (previously presented) The method according to claim 1 wherein the pharmaceutical composition comprises a multiplicity of microparticles.
 - 10.-12. (canceled).

SAFFIE et al.

Appl. No. 10/576,868
October 28, 2009

13. (previously presented) The method of claim 1 in which the porous carrier material has a cytotoxic drug incorporated into the pores thereof to deliver a cytotoxic drug at a dose higher than the LD50 of the corresponding free drug.

14. (previously presented) The method according to claim 13 wherein the cytotoxic drug is selected from chlorambucil and paclitaxel.

15.-17. (canceled).

18. (previously presented) A method for treating a cancer by chemo-brachytherapy comprising introducing to the site at which the cancer is located a pharmaceutical composition comprising a porous silicon carrier material and a cytotoxic agent selected from chlorambucil and paclitaxel.

19. (canceled).

20. (withdrawn) A method according to claim 18 wherein the pharmaceutical composition is introduced to the site at which the cancer is located by injecting a suspension of microparticles into an artery or vein connected to or located in the organ in which the cancer tumour is located.

21. (previously presented) A method according to claim 18 wherein the pharmaceutical composition is introduced to the site at which the cancer is located by injecting a suspension of microparticles into the cancer tumour.